We narrowed to 304 results for: LAS

#105547-AAVrg

Ready-to-use AAV Retrograde particles produced from pENN.AAV.EF1a.eGFP.WPRE.rBG (#105547). In addition to the viral particles, you will also receive purified pENN.AAV.EF1a.eGFP.WPRE.rBG plasmid DNA. EF1a-driven EGFP expression. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

Oct. 18, 2021

Academic Institutions and Nonprofits only

#135424-AAV1

Ready-to-use AAV1 particles produced from pAAV-syn-jYCaMP1s (#135424). In addition to the viral particles, you will also receive purified pAAV-syn-jYCaMP1s plasmid DNA. Synapsin-driven expression of calcium sensor YCaMP1s. These AAV preparations are suitable purity for injection into animals.

Kaspar Podgorski

Mohr et al Nat Methods. 2020 May 25. pii: 10.1038/s

July 22, 2020

Academic Institutions and Nonprofits only

#37825-MaCPNS2

Ready-to-use AAV MaCPNS2 particles produced from pAAV-CAG-GFP (#37825). In addition to the viral particles, you will also receive purified pAAV-CAG-GFP plasmid DNA. These AAV were produced with the MaCPNS2 serotype, which permits efficient transduction of the PNS in rodents (including ENS in rats) and the CNS and PNS (including ENS) in marmosets and rhesus macaques. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Nov. 9, 2023

Academic Institutions and Nonprofits only

#105547-AAV2

Ready-to-use AAV2 particles produced from pENN.AAV.EF1a.eGFP.WPRE.rBG (#105547). In addition to the viral particles, you will also receive purified pENN.AAV.EF1a.eGFP.WPRE.rBG plasmid DNA. EF1a-driven EGFP expression. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

Oct. 18, 2021

Academic Institutions and Nonprofits only

#105531-AAV8

Ready-to-use AAV8 particles produced from pAAV.CMV.LacZ.bGH (#105531). In addition to the viral particles, you will also receive purified pAAV.CMV.LacZ.bGH plasmid DNA. CMV-driven LacZ expression control. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

June 29, 2018

Academic Institutions and Nonprofits only

#105547-AAV5

Ready-to-use AAV5 particles produced from pENN.AAV.EF1a.eGFP.WPRE.rBG (#105547). In addition to the viral particles, you will also receive purified pENN.AAV.EF1a.eGFP.WPRE.rBG plasmid DNA. EF1a-driven EGFP expression. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

May 4, 2018

Academic Institutions and Nonprofits only

#176761-AAV9

Ready-to-use AAV9 particles produced from pZac2.1-GfaABC1D-lck-jGCaMP8s (#176761). In addition to the viral particles, you will also receive purified pZac2.1-GfaABC1D-lck-jGCaMP8s plasmid DNA. GfaABC1D-driven expression of membrane-bound calcium sensor GCaMP8s. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Feb. 24, 2023

Academic Institutions and Nonprofits only

#26973-AAV2

Ready-to-use AAV2 particles produced from pAAV-hSyn-hChR2(H134R)-EYFP (#26973). In addition to the viral particles, you will also receive purified pAAV-hSyn-hChR2(H134R)-EYFP plasmid DNA. hSyn-driven, humanized channelrhodopsin H134R mutant fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Sept. 27, 2024

Academic Institutions and Nonprofits only

#79871-AAV1

Ready-to-use AAV1 particles produced from pAAV-Ef1a-DIO_EGFP-GFE3 (#79871). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO_EGFP-GFE3 plasmid DNA. EF1a-driven, Cre-dependent expression of GFP-GFE3. These AAV preparations are suitable purity for injection into animals.

Don Arnold

Gross et al Nat Methods. 2016 Jun 6. doi: 10.1038/nm

Nov. 13, 2025

Academic Institutions and Nonprofits only

#135635-AAV1

Ready-to-use AAV1 particles produced from pAAV-S5E2-Gq-P2A-dTomato (#135635). In addition to the viral particles, you will also receive purified pAAV-S5E2-Gq-P2A-dTomato plasmid DNA. Expression of Gq-DREADD and dTomato (physically separate) under the control of the E2 regulatory element. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Nov. 29, 2021

Academic Institutions and Nonprofits only

#135633-AAV9

Ready-to-use AAV9 particles produced from pAAV-S5E2-C1V1-eYFP (#135633). In addition to the viral particles, you will also receive purified pAAV-S5E2-C1V1-eYFP plasmid DNA. Expression of red-shifted opsin C1V1 fused to EYFP under the control of the E2 regulatory element. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Aug. 27, 2021

Academic Institutions and Nonprofits only

#135633-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV-S5E2-C1V1-eYFP (#135633). In addition to the viral particles, you will also receive purified pAAV-S5E2-C1V1-eYFP plasmid DNA. Expression of red-shifted opsin C1V1 fused to EYFP under the control of the E2 regulatory element. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Aug. 27, 2021

Academic Institutions and Nonprofits only

#35512-AAV2

Ready-to-use AAV2 particles produced from pAAV-CaMKIIa-hChR2(E123T/T159C)-mCherry (#35512). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-hChR2(E123T/T159C)-mCherry plasmid DNA. CaMKIIa-driven, humanized channelrhodopsin E123T/T159C mutant fused to mCherry for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Mattis et al Nat Methods. 2011 Dec 18;9(2):159-72. do

Nov. 13, 2025

Academic Institutions and Nonprofits only

#213936-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV_BiPVe4_dTomato_nlsdTomato (#213936). In addition to the viral particles, you will also receive purified pAAV_BiPVe4_dTomato_nlsdTomato plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato under the control of the chandelier cell-targeting enhancer E4. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Dec. 2, 2024

Academic Institutions and Nonprofits only

#213941-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV_BiPVe3_ChR2_mCherry (#213941). In addition to the viral particles, you will also receive purified pAAV_BiPVe3_ChR2_mCherry plasmid DNA. Expression of mCherry-tagged channelrhodopsin-2 under the control of the PV+ basket cell-targeting enhancer E3. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Dec. 2, 2024

Academic Institutions and Nonprofits only

#213945-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV_BiSSTe4_ChR2_mCherry (#213945). In addition to the viral particles, you will also receive purified pAAV_BiSSTe4_ChR2_mCherry plasmid DNA. Expression of mCherry-tagged channelrhodopsin-2 under the control of the SST interneuron-targeting enhancer E4. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Dec. 2, 2024

Academic Institutions and Nonprofits only

#135633-AAV1

Ready-to-use AAV1 particles produced from pAAV-S5E2-C1V1-eYFP (#135633). In addition to the viral particles, you will also receive purified pAAV-S5E2-C1V1-eYFP plasmid DNA. Expression of red-shifted opsin C1V1 fused to EYFP under the control of the E2 regulatory element. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Aug. 27, 2021

Academic Institutions and Nonprofits only

#213855-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV_BiVIPe4_dTomato_nlsdTomato (#213855). In addition to the viral particles, you will also receive purified pAAV_BiVIPe4_dTomato_nlsdTomato plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato under the control of the VIP interneuron-targeting enhancer E4. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Dec. 2, 2024

Academic Institutions and Nonprofits only

#213944-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiSSTe4_dTomato_nlsdTomato (#213944). In addition to the viral particles, you will also receive purified pAAV_BiSSTe4_dTomato_nlsdTomato plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato under the control of the SST interneuron-targeting enhancer E4. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213815-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV_BiSSTe10_ChR2_mCherry (#213815). In addition to the viral particles, you will also receive purified pAAV_BiSSTe10_ChR2_mCherry plasmid DNA. Expression of mCherry-tagged channelrhodopsin-2 under the control of the SST interneuron-targeting enhancer E10. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Dec. 2, 2024

Academic Institutions and Nonprofits only